Dr. Zhang on Toxicities of Treatments in RCC

Tian Zhang, MD
Published: Tuesday, Jan 09, 2018



Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the tolerability of agents used for the treatment of patients with renal cell carcinoma (RCC).

Patients have tolerated immunotherapy very well in RCC, explains Zhang. There are current ongoing phase III trials investigating immunotherapy in combination with VEGF inhibitors randomized against sunitinib (Sutent) in the first-line setting.

Most of these trials have completely enrolled and are awaiting final results which will determine tolerability, explains Zhang.
 


Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the tolerability of agents used for the treatment of patients with renal cell carcinoma (RCC).

Patients have tolerated immunotherapy very well in RCC, explains Zhang. There are current ongoing phase III trials investigating immunotherapy in combination with VEGF inhibitors randomized against sunitinib (Sutent) in the first-line setting.

Most of these trials have completely enrolled and are awaiting final results which will determine tolerability, explains Zhang.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x